Pfizer IncChange company Symbol lookupSelect an option...PFE Pfizer IncTICIX Timothy Plan Israel Common Values Fund Class ICAT Caterpillar IncJHI John Hancock Investors TrustSLGN Silgan Holdings IncGBX Greenbrier Companies IncGOOG Alphabet IncPUCKU Goal Acquisitions CorpPRGO Perrigo Company PLCINBS Intelligent Bio Solutions IncGo
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
|
|
|
|
| |
PFE's position in the Pharmaceuticals industry
| Industry Peers | LLY | MRK | BMY | PCRX | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the... | Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes... Go to LLY summary | Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through... Go to MRK summary | Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical... Go to BMY summary | Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute... Go to PCRX summary |
| 52-Week Change | VS. INDUSTRY | 51.19% | 48.92% | 46.42% | -12.09% |
| Market Cap | VS. INDUSTRY | $351.9B | $278.4B | $172.0B | $2.2B |
| Beta | VS. INDUSTRY | 0.4 | 0.4 | 0.4 | 0.7 |
| Dividend Yield | VS. INDUSTRY | 1.06% | 2.66% | 2.67% | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 55.66x | 18.19x | 26.37x | 119.38x |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $29.2B | $59.0B | $46.7B | $654.1M |
| Profit Margin | VS. INDUSTRY | 20.63% | 26.00% | 14.32% | 3.19% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 18.88% | 28.17% | 3.27% | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 5.34% | 27.84% | 2.79% | 27.42% |
| Data as of |
Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.